BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 121 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 3.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $160 | -41.4% | 22,609 | -41.8% | 0.02% | -52.9% |
| Q2 2023 | $273 | -99.9% | 38,825 | +42.4% | 0.03% | +3.0% |
| Q2 2022 | $288,000 | -1.7% | 27,257 | +51.3% | 0.03% | -5.7% |
| Q1 2022 | $293,000 | -23.9% | 18,017 | -32.7% | 0.04% | -23.9% |
| Q3 2021 | $385,000 | +296.9% | 26,774 | +32.0% | 0.05% | +206.7% |
| Q2 2020 | $97,000 | -2.0% | 20,284 | -58.9% | 0.02% | -21.1% |
| Q1 2020 | $99,000 | -18.9% | 49,335 | +207.7% | 0.02% | +11.8% |
| Q3 2018 | $122,000 | -15.3% | 16,036 | -38.0% | 0.02% | -37.0% |
| Q2 2017 | $144,000 | -57.3% | 25,885 | -35.6% | 0.03% | -65.8% |
| Q1 2017 | $337,000 | +524.1% | 40,190 | +110.3% | 0.08% | +426.7% |
| Q1 2016 | $54,000 | -74.9% | 19,107 | +32.7% | 0.02% | -80.0% |
| Q2 2015 | $215,000 | – | 14,397 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |